Where We Focus
Therapeutic Areas
Deep regulatory and scientific experience on Current Trends across oncology, hematology, immunology, rare diseases, endocrine/metabolic, neurology, cardiovascular, vaccines and other high-impact therapeutic and prophylactic areas.
| Area | Overview (Recent Trends, Regulatory Perspectives; also see our White Papers) |
|---|---|
| Oncology/Hematology | Oncology Oncology development is moving quickly, with precision medicine, biomarker-driven therapies, ADCs, radiopharmaceuticals, and cell and gene therapies reshaping how programs are designed and reviewed. Regulatory success increasingly depends on addressing the right questions early and keeping clinical, diagnostic, CMC, and post-approval plans closely aligned. • Early strategy for biomarkers, patient selection, and companion diagnostics. • Dose optimization that balances efficacy, safety, and tolerability, consistent with FDA initiatives such as Project Optimus. • Appropriate endpoint selection for complex and adaptive trial designs. • Use of ctDNA, measurable residual disease, and other emerging response measures. Hematology Hematology development is moving quickly, with gene and cell therapies, bispecific antibodies, and other targeted treatments creating new options for both inherited blood disorders and hematologic malignancies. From an FDA perspective, success depends on addressing durability, safety, manufacturing consistency, and long-term evidence needs early in development. • Early alignment on patient selection, meaningful endpoints, and durability of response • Benefit–risk and treatment-sequencing strategies for BCMA- and CD19-directed therapies • Recognition that FDA risk-management requirements, including REMS, may evolve as real-world safety experience grows • Proactive management of infection risk, cytokine release syndrome, biomarkers, and measurable residual disease |
| Rare Diseases | Rare-disease development is evolving quickly, with gene therapies, RNA-based treatments, targeted biologics, and individualized approaches opening new possibilities for very small patient populations. From an FDA perspective, early alignment is essential because these programs often rely on limited data, novel endpoints, and highly variable disease courses. • Strong natural-history data and fit-for-purpose external controls • Use of FDA initiatives such as the Rare Disease Endpoint Advancement Pilot, Rare Disease Evidence Principles, and Rare Disease Innovation Hub • Integration of registries, patient-experience data, and prospective clinical evidence • Early planning for expedited pathways and accelerated approval, where appropriate |
| Endocrine/Metabolic | Endocrine and metabolic development is changing quickly, driven by incretin therapies, multi-agonists, oral peptides, and more targeted approaches to obesity, diabetes, and related complications. From an FDA perspective, programs now need to show not only meaningful weight loss or glycemic improvement, but also durable benefit, acceptable tolerability, and broader clinical value. • Alignment with FDA’s evolving guidance for obesity therapies, including trial populations, long-term safety, efficacy assessment, and chronic weight- management claims • Evaluation of durability, lean-mass preservation, cardiovascular outcomes, and effects after treatment discontinuation • Integration of obesity-related complications such as sleep apnea, cardiovascular disease, and metabolic liver disease • Use of validated biomarkers, histology, and clinical-outcome endpoints in MASH development |
| Neurology | Neurologic drug development is moving toward earlier diagnosis and more targeted treatment through disease-modifying antibodies, gene and RNA therapies, precision medicines, digital measures, and blood- or imaging-based biomarkers. From an FDA perspective, these programs must connect biological evidence with meaningful clinical benefit and a clear safety-monitoring plan. • Clinically meaningful cognitive, functional, and neurologic outcome measures • Safety monitoring for risks such as amyloid-related imaging abnormalities • Natural-history data, external controls, novel endpoints, and surrogate biomarkers for rare neurologic diseases • Long-term follow-up, confirmatory evidence, and post-approval safety commitments |
| Cardiovascular Diseases | Cardiovascular development is becoming more closely linked with obesity, diabetes, and kidney disease, as new therapies aim to reduce overall cardiometabolic risk rather than improve a single biomarker. From an FDA perspective, the focus is increasingly on demonstrating meaningful and durable benefits for patients. • • Growing development of RNA-based lipid therapies and treatments targeting lipoprotein(a) • Renewed FDA acceptance of renal-denervation devices supported by controlled trials and post-approval surveillance • Early planning for biomarkers, renal effects, diverse enrollment, long-term safety, and post-marketing evidence • Early FDA engagement before relying on novel surrogate endpoints or technology-enabled measures |
| Vaccines | Vaccine development is moving quickly through mRNA and other adaptable platforms, improved adjuvants, combination products, and faster strain updates. From an FDA perspective, success depends on aligning the clinical, manufacturing, and safety strategy early so that changes can be supported without compromising product consistency or public confidence. • Early agreement on antigen selection, immune-response endpoints, correlates of protection, and immunobridging • Use of FDA’s Platform Technology Designation Program to leverage knowledge from a well-characterized platform across multiple products • Robust lot-consistency studies, assay validation, and potency testing • Planning for cold-chain needs, pediatric use, and maternal immunization • Safety evaluation in large and diverse populations |
| Immunology | Immunology development is becoming more targeted, with selective cytokine and receptor therapies, next-generation biologics, small-molecule modulators, biomarkers, and emerging cell-based approaches offering new ways to treat autoimmune and inflammatory diseases. From an FDA perspective, programs must show meaningful benefit while carefully managing the risks of long-term immune modulation. • Clear disease definitions and identification of relevant patient subgroups • Validated clinical outcome measures and appropriate control of background therapies • Careful assessment of immunogenicity, infection risk, malignancy signals, and vaccination considerations • Long-term safety monitoring for sustained immune suppressiontrials when analytical and functional evidence is sufficiently robust |